Postdoctoral Researchers (MIT)

• Dr. Alessandro Angelini, 2012-2016. Ca’ Foscari University of Venice, Italy, Department of Molecular Sciences and Nanosystems.
• Dr. Michael Traxlmayr, 2013-2015. University of Natural Resources and Life Sciences, Vienna, Austria.
• Dr. James Van Deventer, 2011-2015. Tufts University, Dept. of Chemical and Biological Engineering, Medford, MA
• Dr. Pankaj Karande, 2006-2007. Rensselaer Polytechnic Institute, Dept. of Chemical and Biological Engineering, Troy, NY
• Dr. Wai Lau, 2004-2007. Bristol-Myers Squibb, Waltham, MA
• Dr. Letha Sooter, 2005-2006. Biotechnology consultant
• Dr. Dasa Lipovsek, 2003-2006. Bristol-Myers Squibb, Waltham, MA
• Dr. Andrea Piatesi, 2004-2006.
• Dr. Yong-Sung Kim, 2002-2004. Ajou University, Seoul, Korea
• Dr. Mark J. Olsen, 2002-2004. Crenae Therapeutics, Phoenix, AZ
• Dr. Jennifer R. Cochran, 2002-2004. Stanford University, Dept. of Bioengineering, Stanford, CA
• Dr. Brenda A. Kellogg, 2000-2002. GlaxoSmithKline, Cambridge, MA

Graduate Students (MIT Ph.D)

• Noor Momin. “Engineering, Modeling, and Trialing Intratumoral Immunotherapies for the Treatment of Cancer”, 2021. Nahrendorf lab at MGH, Boston, MA.
• Byong Kang. “Identification and Knockout of Immunodominant Endogenous Retroviral Antigen in Murine Tumor Models”, 2021. Asher Biotherapeutics, South San Francisco, CA.
• Adrienne Rothschilds. “Engineering protein-based modulators of allergic, temporal, and checkpoint blockade anti-cancer immunity”, 2019. Third Rock Ventures, Cambridge, MA.
• Naveen Mehta. “Engineering more potent vaccines for the treatment of cancer and autoimmunity”, 2019. Cullinan Oncology, Cambridge, MA.
• Alison Tisdale. “Engineering new approaches for potentiating and studying EGFR-targeted therapies”, 2019. Immunitas Therapeutics, Waltham, MA.
• Monique Kauke. “Targeting Immunosuppression in the Tumor Microenvironment and Protein-based Antagonism of Oncogenic K-Ras”, 2017.
• Ryan Kelly. “Determinants of Antibody Specificity”, 2017. Genentech, South San Francisco, CA.
• Eric Zhu. “Synergistic Anti-Tumor Immune Response to Combination Immunotherapy Consisting of Anti-Tumor Antibodies, Extended Half-Life Interleukin-2, and Other Immunomodulatory Agents”, 2016. Cygnal Therapeutics, Cambridge, MA.
• Alice Tzeng. “Improving methods for cytokine immunotherapy of cancer “, 2016. Cleveland Clinic, Cleveland, OH.
• Byron Kwan. “Integrin-targeted Cancer Immunotherapy”, 2016. Seagen, Bothell, WA.
• Katie Maass, “Quantitative Analysis of Cellular Processing of Antibody-Drug Conjugates”, 2015. Genentech, South San Francisco, CA.
• Nicole Yang, “Reversibly Neutralized Perfringolysin O for Intracellular Delivery of Macromolecules”, 2015. Chiu Lab, Harvard Medical School, Cambridge, MA.
• Cary Opel, “T Cell Mediated Combination Immunotherapy”, 2015. Gilead, Oceanside, CA.
• Seymour de Picciotto, “Protein Engineering Design Principles for the Development of Biosensors”, 2015. Moderna, Cambridge, MA.
• Tiffany Chen, “Engineering Therapeutic Proteins for Immune Modulation”, 2014. Rubius Therapeutics, Cambridge, MA.
• Xiaosai Yao, “Functional Characterization of Mobilized Tumor Cells”, 2013. Genentech, South San Francisco, CA.
• Jordi Mata-Fink, “Engineering of HIV gp120 by Yeast Surface Display for Neutralizing Antibody Characterization and Immunogen Design”, 2012.
• John Rhoden, “Quantitative analysis of perivascular antibody distribution in solid tumors”, 2012. Fusion Pharmaceuticals, Boston, MA.
• Shuning (Annie) Gai, “Engineering Persistent Interleukin-2 for Cancer Immunotherapy”, 2012. Synthekine, Menlo Park, CA.
• David V. Liu, “Protein Engineering for Cancer Therapy”, 2011. Asher Biotherapeutics, South San Francisco, CA.
• Christopher Pirie , “Engineering Targeted Proteins for Intracellular Delivery of Biotherapeutics “, 2011. HDT Bio, Seattle, WA.
• Jamie Spangler, “Characterization and informed design of downregulating anti-epidermal growth factor receptor antibodies”, 2011. Spangler Lab, John Hopkins University, Baltimore, MD.
• Michael Schmidt, “Engineering Antibodies for Improved Targeting of Solid Tumors”, 2009. Ankyra Therapeutics, Boston, MA
• Kelly Davis Orcutt, “Protein Engineering for Targeted Delivery of Radionuclides to Tumors”, 2009. inviCRO, Boston, MA
• Eileen Higham, “Overcoming Dendritic Cell-Mediated Suppression of T Cell Responses in a Prostate Tumor Environment”, 2009. Intergalactic Therapeutics, Boston, MA
• Margaret Ackerman, “Targeting the Tight Junction: Immunotherapy of Colon Cancer “, 2009. Assistant Professor, Thayer School of Engineering, Dartmouth College, Hanover, NH
• Ben Hackel, “High affinity Fn3 engineering”, 2009. Assistant Professor, Chemical Engineering and Materials Science, University of Minnesota.
• Stephen Sazinsky, “Aglycosylated IgGs with enhanced immune effector function”, 2008. Verseau Therapeutics, Bedford, MA
• Shanshan Howland, “Yeast based cancer vaccines,” 2008. Singapore Immunology Network, Singapore
• Greg Thurber, “Tumor targeting with antibodies,” 2008. Assistant Professor, Chemical Engineering, University of Michigan.
• Ginger (Chao) Rakestraw, “Anti-EGFR antibody engineering,” 2007. Bristol-Myers Squibb, Waltham, MA
• Shaun M. Lippow, “Computational analysis, design, and experimental validation of antibody binding affinity improvements beyond in vivo maturation,” 2007. Atreca, San Carlos, CA
• Stefan Zajic, “Improved methods and reagents for pretargeted radioimmunotherapy of cancer,” 2006. GlaxoSmithKline, Upper Providence, PA
• J. Andrew Rakestraw, “A directed evolution approach to engineering recombinant protein production in S. cerevisiae,” 2006. Repertoire Immune Medicines, Cambridge, MA
• David W. Colby, “Isolation, engineering, and characterization of intracellular antibodies specific for the huntingtin protein,” 2005. University of Delaware
• Y. Andrew Yeung, 2005. Asher Biotherapeutics, South San Francisco, CA
• Jeffrey S. Swers, “Isolation and engineering of a high-affinity antibody against P-selectin glycoprotein Ligand-1 (PSGL-1),” 2005.
• Balaji M. Rao, 2004. Assistant Professor Dept. of Chemical Engineering, North Carolina State University
• Katarina Midelfort, “Biophysical characterization of high affinity engineered single-chain Fv antibody fragments,” 2004. DSM Nutritional Products, Lexington, MA
• Christilyn P. Graff, “Antibody Engineering for Tumor Immunotherapy,” 2002. Biogen, Cambridge, MA

Postdoctoral Researchers (University of Illinois)

• Dr. Won Shik Kwon, 1997-1998.

Graduate Students (University of Illinois Ph.D)

• Bannister, Sarah, “Increasing Heterologous Protein Secretion from the Yeast S. cerevisiae Through Manipulation of Cellular Redox Factors,” 2000. Associate Director, Alternative and Public Interest Careers, US Department of State.
• VanAntwerp, Jennifer, “Affinity Maturation of the D1.3 Antibody Using Yeast Surface Display and Flow Cytometry,” 1999. Calvin College, Grand Rapids, MI
• Shusta, Eric, “The Production of Recombinant Immunoglobulin Superfamily Proteins in the Yeast Saccharomyces cerevisiae,” 1999. University of Wisconsin at Madison, Madison, WI
• Boder, Eric, “Molecular Engineering of a Single Chain Fv Antibody Fragment to Femtomolar Affinity,” 1999. University of Tennessee – Knoxville.
• Kowalski, Jean, “The Effect of Stability and Surface Charge Distribution on Secretion of Bovine Pancreatic Trypsin Inhibitor from Yeast,” 1998.
• Parekh, Rajesh, “Disulfide Formation Kinetics of a Model Protein (BPTI) in Yeast,” 1996. Leader of McKinsey’s Asia Pharmaceuticals and Medical Products Practice, McKinsey & Co.
• Shaw, Mark, “Gene Amplification for the Improved Secretion of Foreign Proteins in the Yeast Saccharomyces cerevisiae,” 1995. Senior R&D Manager, BD Biosciences, San Diego, CA.
• Caron Farrell, “Targeting and Translocation Mechanisms in the Secretory Pathway of the Yeast Saccharomyces cerevisiae,” 1995. Pediatrician, TX
• Robinson, Anne, “The Role of BiP and PDI in Foreign Protein Secretion in Yeast,” 1994 (co-advised with Prof. Douglas Lauffenburger). Carnegie Mellon University, Pittsburgh, PA.